Literature DB >> 15767544

Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth.

Jonathan D Cheng1, Matthildi Valianou, Adrian A Canutescu, Eileen K Jaffe, Hyung-Ok Lee, Hao Wang, Jack H Lai, William W Bachovchin, Louis M Weiner.   

Abstract

Tumor-associated fibroblasts are functionally and phenotypically distinct from normal fibroblasts that are not in the tumor microenvironment. Fibroblast activation protein is a 95 kDa cell surface glycoprotein expressed by tumor stromal fibroblasts, and has been shown to have dipeptidyl peptidase and collagenase activity. Site-directed mutagenesis at the catalytic site of fibroblast activation protein, Ser624 --> Ala624, resulted in an approximately 100,000-fold loss of fibroblast activation protein dipeptidyl peptidase (DPP) activity. HEK293 cells transfected with wild-type fibroblast activation protein, enzymatic mutant (S624A) fibroblast activation protein, or vector alone, were inoculated subcutaneously into immunodeficient mouse to assess the contribution of fibroblast activation protein enzymatic activity to tumor growth. Overexpression of wild-type fibroblast activation protein showed growth potentiation and enhanced tumorigenicity compared with both fibroblast activation protein S624A and vector-transfected HEK293 xenografts. HEK293 cells transfected with fibroblast activation protein S624A showed tumor growth rates and tumorigenicity potential similar only to vector-transfected HEK293. In vivo assessment of fibroblast activation protein DPP activity of these tumors showed enhanced enzymatic activity of wild-type fibroblast activation protein, with only baseline levels of fibroblast activation protein DPP activity in either fibroblast activation protein S624A or vector-only xenografts. These results indicate that the enzymatic activity of fibroblast activation protein is necessary for fibroblast activation protein-driven tumor growth in the HEK293 xenograft model system. This establishes the proof-of-principle that the enzymatic activity of fibroblast activation protein plays an important role in the promotion of tumor growth, and provides an attractive target for therapeutics designed to alter fibroblast activation protein-induced tumor growth by targeting its enzymatic activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767544     DOI: 10.1158/1535-7163.MCT-04-0269

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  46 in total

Review 1.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 2.  Vaccine prevention of cancer: can endogenous antigens be targeted?

Authors:  Louis M Weiner; Rishi Surana; Joseph Murray
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-23

3.  Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Patrick A McKee
Journal:  Arch Biochem Biophys       Date:  2006-11-17       Impact factor: 4.013

Review 4.  Insidious changes in stromal matrix fuel cancer progression.

Authors:  Fayth L Miles; Robert A Sikes
Journal:  Mol Cancer Res       Date:  2014-01-22       Impact factor: 5.852

5.  Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways.

Authors:  Sarah K Baird; Laura Allan; Christoph Renner; Fiona E Scott; Andrew M Scott
Journal:  Clin Exp Metastasis       Date:  2015-05-21       Impact factor: 5.150

6.  Activation of EDTA-resistant gelatinases in malignant human tumors.

Authors:  Donghai Chen; Alanna Kennedy; Jaw-Yuan Wang; Wei Zeng; Qiang Zhao; Michael Pearl; Mengzhen Zhang; Zhenhe Suo; Jahn M Nesland; Yuhuan Qiao; Ah-Kau Ng; Naoko Hirashima; Tetsu Yamane; Yoshiyuki Mori; Masako Mitsumata; Giulio Ghersi; Wen-Tien Chen
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

7.  Selective fluorescence probes for dipeptidyl peptidase activity-fibroblast activation protein and dipeptidyl peptidase IV.

Authors:  Koon Siew Lai; Nan-Hui Ho; Jonathan D Cheng; Ching-Hsuan Tung
Journal:  Bioconjug Chem       Date:  2007-05-10       Impact factor: 4.774

8.  Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.

Authors:  Angela Pennisi; Xin Li; Wen Ling; Sharmin Khan; Dana Gaddy; Larry J Suva; Bart Barlogie; John D Shaughnessy; Nazneen Aziz; Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2009-04-08       Impact factor: 6.998

9.  Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours.

Authors:  Osamu Dohi; Haruo Ohtani; Masahito Hatori; Elichi Sato; Masami Hosaka; Hiroshi Nagura; Eiji Itoi; Shoichi Kokubun
Journal:  Histopathology       Date:  2009-10       Impact factor: 5.087

10.  Gene profiling of the erythro- and megakaryoblastic leukaemias induced by the Graffi murine retrovirus.

Authors:  Veronique Voisin; Philippe Legault; Diana Paulina Salazar Ospina; Yaacov Ben-David; Eric Rassart
Journal:  BMC Med Genomics       Date:  2010-01-26       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.